We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 109% below its sector, cheaper than its peers on earnings.
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save B8FK.DE and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
